Among the hematologic malignancies, a Veterans Affairs Health System analysis of 1097 individuals with diabetes and monoclonal gammopathy of undetermined significance (MGUS) found that those who had been exposed to GLP-1 receptor agonist medications had a reduced risk (HR = 0.45) of progression to multiple myeloma.11 This evidence concerns the gene GLP1R and diabetes mellitus.